Safety of Celecoxib in Postoperative Patients With Documented Sulfonamide Allergies

INTRODUCTION: Celecoxib is commonly used for postoperative analgesia because of its favorable adverse effect profile compared with other nonsteroidal anti-inflammatory drugs. However, its use is often restricted in patients labeled as sulfonamide ("sulfa") allergic due to persistent electronic health record warnings, despite contemporary evidence showing minimal risk of immunologic cross-reactivity. The purpose of this study was to evaluate the safety of postoperative celecoxib administration in orthopaedic patients with documented sulfonamide allergies. METHODS: A retrospective cohort study was conducted at a single tertiary academic center. Orthopaedic surgery patients from January 1, 2020, to December 31, 2022, with a documented sulfonamide allergy who received celecoxib postoperatively were included. All postoperative clinic notes, telephone encounters, and emergency department records from surgery through the second follow-up visit were reviewed to identify allergic reactions. RESULTS: Sixty-one patients met inclusion criteria (mean age, 52.6 ± 15.7 years; 67.2% female). The mean time to the first and second postoperative visits was 17 ± 7 and 49 ± 19 days, respectively. Thirteen patients (21.3%) presented to the emergency department during follow-up for issues, including postoperative pain or swelling, gastrointestinal complaints, constipation, unrelated trauma, or noncardiac chest pain. Two patients experienced allergic reactions attributed to perioperative antibiotics or surgical adhesive. One patient (1.6%) sustained a gastrointestinal bleed while also taking aspirin for thromboprophylaxis. No allergic reactions were attributable to celecoxib. CONCLUSIONS: Celecoxib was safely administered to patients with documented sulfonamide allergies, with no evidence of cross-reactivity. Given its analgesic benefits and overall safety profile, routine avoidance of celecoxib in sulfa-allergic patients appears unnecessary. Updating electronic health record decision-support logic to reflect current evidence may reduce alert fatigue and support more effective multimodal pain management.

Authors

Institutions

Publication Details

Journal
Journal of the American Academy of Orthopaedic Surgeons
Published
2026-05-29
DOI
https://doi.org/10.5435/jaaos-d-25-01556
Primary Topic
Drug-Induced Adverse Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety of Celecoxib in Postoperative Patients With Documented Sulfonamide Allergies

Catharina Gaeth, Josiah Snowden, Alex Penner, Kenneth Fellows et al.
Journal of the American Academy of Orthopaedic Surgeons
Drug-Induced Adverse Reactions
article

Safety of Celecoxib in Postoperative Patients With Documented Sulfonamide Allergies

Catharina Gaeth, Josiah Snowden, Alex Penner, Kenneth Fellows, Joseph Burke, Daniel J. Cognetti, Sean Kshir
article en

Abstract

INTRODUCTION: Celecoxib is commonly used for postoperative analgesia because of its favorable adverse effect profile compared with other nonsteroidal anti-inflammatory drugs. However, its use is often restricted in patients labeled as sulfonamide ("sulfa") allergic due to persistent electronic health record warnings, despite contemporary evidence showing minimal risk of immunologic cross-reactivity. The purpose of this study was to evaluate the safety of postoperative celecoxib administration in orthopaedic patients with documented sulfonamide allergies. METHODS: A retrospective cohort study was conducted at a single tertiary academic center. Orthopaedic surgery patients from January 1, 2020, to December 31, 2022, with a documented sulfonamide allergy who received celecoxib postoperatively were included. All postoperative clinic notes, telephone encounters, and emergency department records from surgery through the second follow-up visit were reviewed to identify allergic reactions. RESULTS: Sixty-one patients met inclusion criteria (mean age, 52.6 ± 15.7 years; 67.2% female). The mean time to the first and second postoperative visits was 17 ± 7 and 49 ± 19 days, respectively. Thirteen patients (21.3%) presented to the emergency department during follow-up for issues, including postoperative pain or swelling, gastrointestinal complaints, constipation, unrelated trauma, or noncardiac chest pain. Two patients experienced allergic reactions attributed to perioperative antibiotics or surgical adhesive. One patient (1.6%) sustained a gastrointestinal bleed while also taking aspirin for thromboprophylaxis. No allergic reactions were attributable to celecoxib. CONCLUSIONS: Celecoxib was safely administered to patients with documented sulfonamide allergies, with no evidence of cross-reactivity. Given its analgesic benefits and overall safety profile, routine avoidance of celecoxib in sulfa-allergic patients appears unnecessary. Updating electronic health record decision-support logic to reflect current evidence may reduce alert fatigue and support more effective multimodal pain management.

Journal of the American Academy of Orthopaedic Surgeons
United States Army Medical Command (US), Cognizant (United States) (US), Defense Health Agency (US), Object Research Systems (Canada) (CA)
Peace, Justice and strong institutions
Openalex Percentile: Top 8%
Drug-Induced Adverse Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.